Abrégé

Provided are a diimide derivative represented by formula I, a preparation method therefor and the use thereof. The diimide derivative has a good anti-tumor activity, and the anti-proliferative activity against various cancer cells is significantly better than those of similar compounds. Provided are a diimide derivative represented by formula I, a preparation method therefor and the use thereof. The diimide derivative has a good anti-tumor activity, and the anti-proliferative activity against various cancer cells is significantly better than those of similar compounds.

Classes IPC  ?

• C07D 221/14 - Aza-phénalènes, p. ex. naphtalimide-1, 8
• A61K 31/47 - QuinoléinesIsoquinoléines
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61P 35/00 - Agents anticancéreux
• C07D 221/18 - Systèmes cycliques d'au moins quatre cycles

Abrégé

Disclosed is a composition of cefoperazone sodium and tazobactam sodium. High performance liquid chromatography analysis of the composition shows that the composition has specific chromatogram characteristics. The composition can be combined with another agent to form a significantly stable product. When the composition is combined with a solution for injection, the resulting solution can have a stable pH value and a stable degree of clarity for a long time. When the composition is used to prepare a drug, the drug will have a good therapeutic effect and a low risk of adverse reactions. Further disclosed is a quality control method for cefoperazone sodium and tazobactam sodium, with which the quality of the composition can be efficiently controlled to obtain a drug capable of being combined with another agent to form a product with excellent stability. The present invention can offer benefits for improving drug quality, medication safety, effectiveness, and the like, thus having good application prospects.

Classes IPC  ?

• A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine
• A61P 31/04 - Agents antibactériens
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/431 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes contenant d'autres systèmes hétérocycliques, p. ex. ticarcilline, azlocilline, oxacilline

Abrégé

Provided is a fused ring diimide derivative having a chemical structure of formula I. Further provided is a preparation method therefor. The fused ring diimide derivative has excellent anti-tumor activity, and the anti-proliferative activity on various cancer cells is significantly better than that of similar compounds. Provided is a fused ring diimide derivative having a chemical structure of formula I. Further provided is a preparation method therefor. The fused ring diimide derivative has excellent anti-tumor activity, and the anti-proliferative activity on various cancer cells is significantly better than that of similar compounds.

Classes IPC  ?

• C07D 221/14 - Aza-phénalènes, p. ex. naphtalimide-1, 8
• C07D 209/66 - Naphto [c] pyrrolesNaphto [c] pyrroles hydrogénés avec des atomes d'oxygène en positions 1 et 3
• C07D 221/18 - Systèmes cycliques d'au moins quatre cycles
• C07D 491/06 - Systèmes condensés en péri
• A61P 35/00 - Agents anticancéreux

Abrégé

Provided are a diimide derivative, a preparation method therefor and the use thereof. The diimide derivative has a good anti-tumor activity, and the anti-proliferative activity against various cancer cells is significantly better than those of similar compounds. (I)

Classes IPC  ?

• C07D 221/14 - Aza-phénalènes, p. ex. naphtalimide-1, 8
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61P 35/00 - Agents anticancéreux

Abrégé

A drug, food and application of an anti-coronavirus infection, the drug or food containing lysozyme or a combination that comprises lysozyme; the lysozyme or a combination thereof can be used to prepare a drug for anti coronavirus infection and preventing or treating coronavirus-related diseases or symptoms, or food for assisting in anti coronavirus infection and assisting in preventing or treating coronavirus-related diseases or symptoms. The present disclosure has a good preventive and therapeutic effect on coronavirus infection or related diseases or symptoms thereof; in addition, the present application can accelerate the elimination of the virus in vivo, accelerate the speed of coronavirus nucleic acid tests in vivo turning negative, shorten the course of a patient's illness, effectively prevent and reduce the spread of coronavirus, and also has important social benefits and good application prospects.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

Disclosed are a pharmaceutical composition containing cefoperazone sodium and tazobactam sodium, and an application thereof. In the pharmaceutical composition, the weight ratio of cefoperazone sodium to tazobactam sodium is 6:1. In the treatment of renal insufficiency combined with bacterial infection, the pharmaceutical composition can effectively increase clinical efficacy and also significantly reduce the incidence of adverse reactions, thereby excellently ensuring efficacy and safety. Also provided is a pharmaceutical composition that effectively reduces the production of related substances, significantly increasing the quality of the product containing cefoperazone sodium and tazobactam sodium in a ratio of 6:1, and can further ensure stability of the drug in use as well as during storage and transportation.

Classes IPC  ?

• A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 31/04 - Agents antibactériens
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 13/02 - Médicaments pour le traitement des troubles du système urinaire de l'urine ou des voies urinaires, p. ex. acidificateurs d'urine
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/431 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes contenant d'autres systèmes hétérocycliques, p. ex. ticarcilline, azlocilline, oxacilline

Abrégé

Disclosed is a drug combination for preventing or treating irritable bowel syndrome. The drug combination comprises dosmalfate and lysozyme.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine

Abrégé

The use of lysozyme or combinations comprising the lysozyme in preparing a medicament for preventing or treating the novel coronavirus pneumonia COVID-19 and in preparing a food for assisting in preventing or treating the novel coronavirus pneumonia COVID-19 is disclosed. The lysozyme or the combination of the lysozyme, as provided by the present invention, can effectively inhibit cell damage caused by the novel coronavirus, inhibit the inflammatory factors expression induced by the novel coronavirus, ameliorate airway obstruction and decreased expiratory volume caused by lung lesions, and ameliorate intestinal barrier dysfunction. The lysozyme or the combination of the lysozyme has good effects on patients with high viral load, respiratory distress, impaired intestinal function, etc., and can reduce the novel coronavirus infection rate and the incidence rate of severe novel coronavirus pneumonia.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
• A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
• A61K 31/4965 - Pyrazines non condensées
• A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
• A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
• A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
• A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 38/21 - Interférons

Abrégé

The embodiments of the present invention relate to the technical field of medicine, in particular to a β-lactamase inhibitor composition with a stable quality, the use thereof and a method therefor. The pharmaceutical composition of the embodiments of the present invention has improved hygroscopicity and better stability, so that the stability of materials in a preparation process can be ensured, and the pharmaceutical composition is particularly suitable for further preparing compound antibiotics. Moreover, experiments show that the β-lactamase inhibitor composition of the embodiments of the present invention can better improve the sensitivity of antibiotics to drug-resistant bacteria, and the prepared compound antibiotics have a stronger antimicrobial activity to drug-resistant bacteria.

Classes IPC  ?

• A61K 31/43 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes
• A61K 31/431 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes contenant d'autres systèmes hétérocycliques, p. ex. ticarcilline, azlocilline, oxacilline
• A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine
• A61P 31/04 - Agents antibactériens

Abrégé

Disclosed in the present invention is use of lysozyme in the preparation of a drug for preventing or treating a uric acid-related disease, a drug for reducing uric acid, and a drug for promoting uric acid excretion. Also disclosed in the present invention are a pharmaceutical composition for preventing or treating a uric acid-related disease, a pharmaceutical composition for reducing uric acid, and a pharmaceutical composition for promoting uric acid excretion, and a method for preventing or treating a uric acid-related disease, reducing uric acid and promoting uric acid excretion.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61P 19/06 - Agents antigoutte, p. ex. agents antihyperuricémiants ou uricosuriques
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

Disclosed are a pharmaceutical composition containing lysozyme and the use thereof in the preventing psoriasis, treating of psoriasis, and/or preventing of psoriasis recurrence. The pharmaceutical composition can significantly prolong the time before disease recurrence and significantly reduce the recurrence rate of diseases compared with the use of traditional oral drugs, immunosuppressive agents, biological agents, etc.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 17/06 - Antipsoriasiques
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

A compound for regulating body weight imbalance, a composition thereof and an application thereof. The inventor unexpectedly discovered that diosmin hydrogen sulfate derivatives have the effects of regulating body weight imbalance, and are expected to be developed as safe and effective weight imbalance regulators or used as synergists to improve the regulatory effects of existing weight imbalance regulators.

Classes IPC  ?

• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61P 3/04 - AnorexigènesMédicaments de l'obésité

Abrégé

Acinetobacter baumannii infection, characterized in the following: by mass, the amount of ceftazidime used in the sulbactam and ceftazidime composition comprising 10% to 90% of the amount of sulbactam used.

Classes IPC  ?

• A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame
• A61K 31/43 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes
• A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine
• A61P 31/04 - Agents antibactériens

Abrégé

Provided is a combination for lowering blood sugar, comprising lysozyme and dosmalfate. Also provided are an application of the composition and a method for the composition. Lysozyme and dosmalfate have significant synergistic effects in lowering blood sugar, and can improve gastrointestinal dysfunction of hyperglycemic patients. In addition, the combination also has synergistic and attenuating effects on other hypoglycemic drugs, and therefore has a particular clinical value for blood sugar lowering and hyperglycemia related diseases or symptoms.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques

Abrégé

Provided is a fused ring diimide derivative having a chemical structure as represented by formula I. Further provided is a preparation method therefor. The fused ring diimide derivative has excellent anti-tumor activity, and the anti-proliferative activity on various cancer cells is significantly better than that of similar compounds.

Classes IPC  ?

• C07D 221/14 - Aza-phénalènes, p. ex. naphtalimide-1, 8
• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• A61P 35/00 - Agents anticancéreux

Abrégé

A combination for treating Alzheimer's disease and a use thereof, specifically, a combination based on Modafinil and acetaminophen, and a use thereof for preparing a drug to treat Alzheimer's disease. According to research, when combining Modafinil and acetaminophen for treating Alzheimer's disease, the effect of Modafinil is significantly enhanced by acetaminophen, and test results show that the combination of the two has a synergistic effect; also, acetaminophen eliminates certain adverse reactions to Modafinil, such as anxiety and tension.

Classes IPC  ?

• A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
• A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61K 31/13 - Amines, p. ex. amantadine
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

Disclosed in the present invention are an application of lysozyme or a combination comprising the lysozyme in preparation of a medicine for preventing or treating COVID-19, and an application in preparation of food for assisting in preventing or treating COVID-19. The lysozyme or the combination thereof provided by the present invention can effectively inhibit cell damage caused by novel coronavirus, inhibit inflammatory factor expression induced by novel coronavirus, improve airway obstruction and expiratory volume reduction caused by pulmonary lesions, and improve intestinal barrier dysfunction. The lysozyme or the combination thereof has a good effect on high virus load, respiratory distress, intestinal function impairment and the like of patients, and can reduce the infection rate of novel coronavirus and severe cases of COVID-19. In addition, because the lysozyme is extremely high in safety, the lysozyme also has a very important value for preventing unconfirmed people at a high risk for infection from infecting novel coronavirus.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 31/12 - Antiviraux

Abrégé

A drug, food and application of an anti-coronavirus infection, the drug or food containing lysozyme or a combination that comprises lysozyme; the lysozyme or a combination thereof can be used to prepare a drug for resisting coronavirus infection and preventing or treating coronavirus-related diseases or symptoms, or food for assisting in resisting coronavirus infection and assisting in preventing or treating coronavirus-related diseases or symptoms. Lysozyme or a combination thereof can effectively inhibit the cell damage and inflammatory reaction caused by coronavirus, relieve symptoms of the digestive system, and improve airway obstruction, decreased expiratory volume and intestinal barrier function. The present invention has a good preventive and therapeutic effect on coronavirus infection or related diseases or symptoms thereof; in addition, the present application can accelerate the elimination of the virus in vivo, accelerate the speed of coronavirus nucleic acid tests in vivo turning negative, shorten the course of a patient's illness, effectively prevent and reduce the spread of coronavirus, and also has important social benefits and good application prospects.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
• A23L 33/17 - Acides aminés, peptides ou protéines

Abrégé

Disclosed is a drug combination for preventing or treating irritable bowel syndrome. The drug combination comprises dosmalfate and lysozyme.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse

Abrégé

Disclosed in the present invention is use of lysozyme in preparation of a drug for preventing or treating a uric acid-related disease, a drug for reducing uric acid, and a drug for promoting uric acid excretion. Also disclosed in the present invention are a pharmaceutical composition for preventing or treating a uric acid-related disease, a pharmaceutical composition for reducing uric acid, a pharmaceutical composition for promoting uric acid excretion, and a method for preventing or treating a uric acid-related disease, reducing uric acid, and promoting uric acid excretion.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61P 19/06 - Agents antigoutte, p. ex. agents antihyperuricémiants ou uricosuriques
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins

Abrégé

Disclosed are a pharmaceutical composition containing lysozyme and the use thereof in preventing psoriasis, treating psoriasis and/or preventing psoriasis recurrence. The pharmaceutical composition can significantly prolong the time before disease recurrence and significantly reduce the recurrence rate of diseases compared with the use of traditional oral drugs, immunosuppressive agents, biological agents, etc.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61P 17/06 - Antipsoriasiques

Abrégé

A compound for regulating body weight imbalance, a composition thereof and an application thereof. The inventor unexpectedly discovered that diosmin hydrogen sulfate derivatives have the effect of regulating body weight imbalance, and are expected to be developed as safe and effective weight imbalance regulators or used as synergists to improve the regulatory effects of existing weight imbalance regulators.

Classes IPC  ?

• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse

Abrégé

The application of a sulbactam and ceftazidime composition in the preparation of a drug for treating a carbapenem-resistant antibiotic Acinetobacter baumannii infection, characterized in the following: by mass, the amount of ceftazidime used in the sulbactam and ceftazidime composition comprising 10% to 90% of the amount of sulbactam used.

Classes IPC  ?

• A61K 31/545 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine
• A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame
• A61P 31/04 - Agents antibactériens
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques

Abrégé

Provided are a diimide derivative, a preparation method therefor and the use thereof. The diimide derivative has a good anti-tumor activity, and the anti-proliferative activity against various cancer cells is significantly better than those of similar compounds. (I)

Classes IPC  ?

• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• C07D 221/14 - Aza-phénalènes, p. ex. naphtalimide-1, 8
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons